Cargando…

Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients

Monitoring of immunosuppressive drugs, such as calcineurin and mTOR inhibitors, is essential to avoid undesirable kidney transplant outcomes. Polymorphisms in pharmacokinetics-related genes have been associated with variability in blood levels of immunosuppressive drugs and adverse effects, but infl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campos-Salazar, Antony Brayan, Genvigir, Fabiana Dalla Vecchia, Felipe, Claudia Rosso, Tedesco-Silva, Helio, Medina-Pestana, José, Monteiro, Gabriela Vieira, Basso, Rodrigo de Gouveia, Cerda, Alvaro, Hirata, Mario Hiroyuki, Hirata, Rosario Dominguez Crespo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246626/ https://www.ncbi.nlm.nih.gov/pubmed/30487748 http://dx.doi.org/10.3389/fphar.2018.01296

Ejemplares similares

Differential expression of genes related to calcineurin and mTOR signaling and regulatory miRNAs in peripheral blood from kidney recipients under tacrolimus-based therapy
por: Bonezi, Vivian, et al.
Publicado: (2020)

Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients
por: Salgado, Patricia C, et al.
Publicado: (2017)

Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients
por: Llinàs-Mallol, Laura, et al.
Publicado: (2020)

Role of microRNAs 221/222 on Statin Induced Nitric Oxide Release in Human Endothelial Cells
por: Cerda, Alvaro, et al.
Publicado: (2015)

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis
por: Xie, Xishao, et al.
Publicado: (2015)

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review
por: Olszewska, Berenika, et al.
Publicado: (2023)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Impact of Combinations of Donor and Recipient Ages and Other Factors on Kidney Graft Outcomes
por: Gerbase-DeLima, Maria, et al.
Publicado: (2020)

Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin
por: Cerda, Alvaro, et al.
Publicado: (2011)

STIM1 controls calcineurin/Akt/mTOR/NFATC2-mediated osteoclastogenesis induced by RANKL/M-CSF
por: Huang, Yanjiao, et al.
Publicado: (2020)

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
por: Jefferies, Reece, et al.
Publicado: (2022)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
por: Cerda, Alvaro, et al.
Publicado: (2021)

The impact of universal induction therapy on early hospital readmission of kidney transplant recipients
por: Tavares, Melissa Gaspar, et al.
Publicado: (2022)

Reviewing 15 years of experience with sirolimus
por: Tedesco Silva, Helio, et al.
Publicado: (2015)

Calcineurin inhibitor toxicity in a renal transplant recipient
por: Charney, Douglas A., et al.
Publicado: (2009)

Urological Complications Associated With Pyeloureterostomy Without Ipsilateral Nephrectomy in Renal Transplant Recipients
por: Neto, Hernani M., et al.
Publicado: (2022)

Calcineurin Inhibitor-Induced and Ras-Mediated Overexpression of VEGF in Renal Cancer Cells Involves mTOR through the Regulation of PRAS40
por: Basu, Aninda, et al.
Publicado: (2011)

mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
por: Granata, Simona, et al.
Publicado: (2021)

The effect of calcineurin inhibitors on anthropometric measurements in kidney transplant recipients
por: Sayilar, Emel Isiktas, et al.
Publicado: (2022)

Predictors of mortality in renal transplant recipients with severe sepsis and septic shock
por: de Carvalho, Mônica Andrade, et al.
Publicado: (2013)

Clinical validation of a liquid chromatography-tandem mass spectrometry method for the quantification of calcineurin and mTOR inhibitors in dried matrix on paper discs
por: Bressán, Ignacio Guillermo, et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

Transition from antigenemia to quantitative nucleic acid amplification testing in cytomegalovirus-seropositive kidney transplant recipients receiving preemptive therapy for cytomegalovirus infection
por: Nakamura, Mônica Rika, et al.
Publicado: (2022)

Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?
por: Geissler, Edward K
Publicado: (2015)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Role of mTOR Signaling in Tumor Microenvironment: An Overview
por: Conciatori, Fabiana, et al.
Publicado: (2018)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Modulation of the mTOR Pathway by Curcumin in the Heart of Septic Mice
por: Rattis, Bruna A. C., et al.
Publicado: (2022)

Mortality Predictors in Renal Transplant Recipients with Severe Sepsis and Septic Shock
por: de Carvalho, Mônica Andrade, et al.
Publicado: (2014)

Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death
por: Tosello, Valeria, et al.
Publicado: (2016)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Exploring mTOR inhibition as treatment for mitochondrial disease
por: Sage‐Schwaede, Abigail, et al.
Publicado: (2019)

mTOR Cross-Talk in Cancer and Potential for Combination Therapy
por: Conciatori, Fabiana, et al.
Publicado: (2018)

Protocol for the assessment of mTOR activity in mouse primary hepatocytes
por: Plata-Gómez, Ana Belén, et al.
Publicado: (2021)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cr1i07e57929atdu5fvc3ui3c6